Compare Microchip Technology Inc. (MCHP) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Tango Therapeutics Inc. — how do they compare? Microchip Technology Inc. trades at $70.76 (market cap $40.27B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Microchip Technology Inc. is far larger — about 10.7× Tango Therapeutics Inc.'s market cap, and Microchip Technology Inc. pays a 2.45% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and Tango Therapeutics Inc. for 0 Days on average.
| MCHP | TNGX | |
|---|---|---|
Market Cap | $40.27B | $3.75B |
Volume | 6,570,711 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $102.97 | $32.90 |
52-Week Low | $49.02 | $7.50 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $45.40B | $2.77B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $71.25, down 3.49% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with strong recent earnings beats but negative net income in 2025. Recent developments include the acquisition of Hailo and expansion of Ethernet and power portfolios targeting automotive and data center markets. Analyst consensus remains strongly bullish with a $110.50 price target despite current weakness.
MCHP faces near-term headwinds from cyclical semiconductor demand but maintains long-term growth potential through AI infrastructure and automotive connectivity. High valuation ratios (P/E 109.06) and significant debt ($5.63B) present risks, while institutional accumulation and product expansion provide upside catalysts. The stock offers 55% upside to consensus target if execution improves.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
